"Part of the agreement may have been the endorsement of the scheme by the board."
My view also.
Plus in an ideal world Pfizer want full control of the Resapp technology. Realising shareholders are unlikely to give it, they will accept the next best option, a partnership. Which is remarkable if true.
BOD Motive?, page-3
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
